Introduction
Effectiveness of evidence-based therapies relies on the execution of treatment plans.
These plans are typically based around pharmacotherapy. Thus, health outcomes are directly related to adherence to medication [1] .
According to the ABC European consensus, medication adherence has been defined as active, cooperative and voluntary participation of the patient in following recommendations from a healthcare provider. It involves three critical steps:
• Initiation, which defines the moment that the patient takes the first dose;
• Implementation, which is related with the extent to which the prescription regimen was followed;
• Discontinuation, which happens when the patient stops taking the prescribed medicine(s) [2] In general, better adherence entails better health outcomes and improved patient quality of life [3] . Moreover, adherence is also one of the major determinants of the costs of health care [4, 5] . Unfortunately, in real life conditions, adherence is far from expected, particularly in the case of chronic conditions: a World Health Organization report has estimated that adherence to long-term therapy for chronic illnesses in developed countries averages 50% only [6] . Data collected for Poland prove that in terms of poor implementation, non-adherence can range from 57.6% in the case of hypertension [7] to 85.6% in the case of psychiatric conditions [8] . Comparative studies also indicate that various forms of non-adherence are more prevalent in Poland than in Western European countries [7, 9] .
So far, most of the studies in this field have focused on poor implementation and discontinuation [10] . However, primary non-adherence is also very important from the public health perspective, due to its negative effect on health outcomes. Moreover, even from a short-term perspective, initial medication non-adherence has a negative impact on productivity and leads to increased net costs [11] .
Polish healthcare system, likewise many other European systems, is a health insurance systems based on a principle of social solidarity. Health services are provided free of charge to those insured (i.e. practically all the population) by both public and private healthcare providers, and are paid by the only national health payer -National Health Fund. Most of drugs are subject to out-of-pocket copayment, which varies within drug classes. Copayment is organized around the idea of stimulating the use of generic drugs: original (brand name) drugs incur higher copayments than the generics. However, there is huge variation of copayment among various generics holding the same active compound. Recently, the '75+ Program' has been introduced, letting those aged 75 and over obtain several drugs for free in community pharmacies, provided that the prescription has been issued by their primary care physician.
These are the drugs shortlisted by the Ministry of Health, due to their important role in evidence-based therapy for chronic conditions in elderly. Currently, the list holds over 2,000 drugs.
So far, primary non-adherence has not been extensively studied in Poland, due to lack of the availability of relevant data. However, the recent implementation of the uniform nationwide eHealth system in Poland creates new opportunity for that sort of studies, enabling comparisons between pharmacy claims data and prescribing data. Once completely implemented, this system will be composed of several interlinked digital health solutions, such as e-prescription, patient electronic health record and e-referral. One of the first solutions to be implemented is e-prescription, which has been extensively piloted in 2018. Along with other major advantages over traditional prescriptions, e-prescription allows primary nonadherence to be traced through the comparison of data regarding prescribed and dispensed edrugs.
Therefore, the aim of this study was to analyze the extent of primary non-adherence in Poland, and to identify major drivers of this behavior among Polish patients.
Patients and Methods
This retrospective analysis used data from all the e-prescriptions issued in Poland in 2018. The entire database included 119,880 e-prescriptions, each for individual drug item.
Most of these prescriptions were issued within the national e-prescription pilot. The pilot was running between May and September, 2018. Participating healthcare institutions of various profiles (such as primary care centers, outpatient specialist clinics, and hospitals) were either invited by CSIOZ (see below), or joined the pilot on the voluntary basis. Thus, the pilot covered 9 voivodeships (out of total 16), and included 190 physicians.
The data used in this study was obtained from the Center of Information Systems for Healthcare (Centrum Systemów Informacyjnych Ochrony Zdrowia, CSIOZ). CSIOZ is a governmental institution responsible for the digitalization of the Polish healthcare system.
One of its major tasks is building up a nationwide system of electronic prescriptions.
The source data was fully anonymized; therefore, according to the policy of Ethical Commission of Medical University of Lodz, the study was not subject to ethical approval.
The data was also simplified: along with basic characteristic of the patient (namely: age and gender), each record included the date of prescribing, details of the drug prescribed, date of dispensation (if it took place), and details of the drug being dispensed.
Primary non-adherence is often defined as failure to have a new prescription dispensed within a defined number of days after the medication was ordered [12] . Our data, however, was not linked to clinical data, nor were the longitudinal prescription histories for individual patients available. Therefore, for the purpose of this study, primary non-adherence was defined as the e-prescription being not dispensed within a period of 30 days, which corresponds with the typical period of prescription validity in Poland.
In order to perform an in-depth analysis of the drivers of non-adherence, 47 drugs of key importance for public health were selected. These belonged to six major therapeutic areas and were derived from 16 drug classes, as detailed below, along with their corresponding ATC codes: For further analysis, Anatomical Therapeutic Chemical classification system (ATC) codes were assigned according to the drug trade names originally provided on the eprescriptions. Thus, different drugs sharing the same chemical compound were classified under the same ATC code. Only drugs formed from a single chemical compound were included in this analysis, fixed-dose combination drugs were ignored.
Statistical analysis
Data analysis included descriptive statistics of overall prevalence of primary non-adherence.
Then, the effect of potential drivers of primary non-adherence was assessed, these including patient characteristics (age and gender), drug class, and special care program ('75+ Program').
For the purpose of this analysis, age (a continuous variable) was categorized into five categories: 1-18, 19-39, 40-64, 65-74 and 75+ years. Due to low number of patients in two youngest age groups, for the purpose of logistic regression analysis these two groups were combined. Categorical variables were expressed as proportions and compared between relevant groups using chi-square tests.
In addition to the descriptive analyses, multivariable analysis was performed with age and gender accepted as independent variables, and primary non-adherence as a single dependent variable. In order to determine which of these factors, if any, were independently associated with primary non-adherence in our study population, a logistic regression was employed. This let the calculation of relevant odds ratios and 95% confidence intervals. For statistical calculations, Statistica 10 software (TIBCO Software Inc.) was used.
Results

e-prescription characteristics
Out of all 119,880 e-prescriptions issued in Poland in 2018, nearly ¾ (72,149, i.e. 60.2%) were prescribed to female patients. Only 806 e-prescriptions (0.7% of all) were prescribed to those aged up to 18 years, whereas the highest number of e-prescriptions was issued for the 40-64 year age group (40,742; 34.0%). Altogether, prescriptions for elderly, i.e. those aged 65+, represented 57.3% (68,692) of the total number of e-prescriptions; of these, nearly half were issued for those aged 75+ (Table 1) .
Primary non-adherence
Out of all e-prescriptions issued in Poland in 2018, 94.913 were filled in, thus making the level of primary non-adherence 20.8% (Table 1) .
Across all e-prescriptions, literally identical percentages was unfilled in case of eprescriptions issued for female and male patients (20.8%, and 20.8%, P=0.97). On the other hand, age demonstrated a significant effect on primary non-adherence, with the lowest level of non-adherence found in e-prescriptions issued for the oldest group (36.9% of eprescriptions unfilled in age group 1-18, vs 16.1% in those aged 75+; across-group chi2 = 1,802.44, P<0.001) ( Table 1) .
Primary non-adherence in the subgroup of e-prescription issued for selected drugs of key importance
For the group of selected drugs of key importance, 47,492 e-prescriptions were issued, of which 27,826 (58.6%) were prescribed for female patients. In this sample, primary nonadherence level reached 17.0% ( Table 2) .
The univariable analysis found gender to have no effect on primary non-adherence in the selected drug sample, with primary non-adherence occurring in 16.8% of e-prescriptions issued to women, and 17.3% to men (P=0.13). Also in this sample, primary non-adherence was found to correlate with age, with the lowest level of primary non-adherence observed in patients aged 75+ (Figure 1 ). Multivariable analysis confirmed that the odds for nonadherence decreased with age, reaching a low of OR=1.81 (95% CI 1.57-2.09) for those aged 75+ ( Table 3 ).
Significant variability in non-adherence was observed across therapeutic areas, drug classes and individual drugs ( Table 2 ). Out of the therapeutic areas, the lowest rate of dispensation failure was observed for e-prescriptions for antibiotics (14.3%), followed by antidiabetic agents (14.9%); in contrast, the highest rates were observed for antithrombotic agents, lipid lowering agents, and antidepressants (18.1%, 17.9%, and 17.8%, respectively).
Among drug classes, the lowest levels of primary non-adherence were observed for sulphonylureas and platelet aggregation inhibitors (13.2%, and 14.2%, respectively), and the highest for fibrates and direct thrombin inhibitors (20.3%, and 20.2%, respectively). Finally, with regard to individual drugs, the least primary non-adherence was observed with roxithromycin, diltiazem and gliclazide (0.0%, 4.3%, and 10.3%, respectively) and the highest with dabigatran, venlafaxine and eplerenone (29.3%, 26.8% and 22.8%) ( Figure 2 ). However, it is important to note that only a limited number of e-prescriptions were issued for both roxithromycin and diltiazem.
Several drugs belonging to the sample were covered by the '75+ Program'. As illustrated in Figure 3 , prescriptions for drugs covered by this program were unfilled less often than the drugs that were not (16.9% vs 19.9%, respectively; P<0.001).
Discussion
This study is the first large-scale assessment of primary non-adherence in Poland. Our results clearly indicate that a substantial proportion of issued e-prescriptions, i.e. one out of five, was not collected. However, this figure merits some further justification. Some of the uncollected e-prescriptions were issued for items of lower importance, such as over-thecounter drugs available in pharmacies, dietary supplements or even cosmetics. Despite this, the percentage of unfulfilled e-prescriptions issued for selected drugs of major importance is of more concern. Although the level of primary non-adherence in this sample was still high (17.0%), it is comparable to such values found in other countries, ranging from 6.3% for statins and 8.0% for antidepressants in Iceland [13] , through 5.6% for oral anticoagulation drugs in Spain [14] , 9.3% for all drugs in Denmark [15] , 13.1% for drugs used in osteoporosis in Estonia [16] , 14.9% for antidepressants in Sweden [17] to 15% for antidepressants in Catalonia [18] . In a small study in Portugal, primary non-adherence reached 22.8% [19] .
Perhaps the largest European cohort studied so far, i.e. approximately 1.6 million Catalonian patients with 2.9 million prescriptions, indicated 17.6% primary non-adherence for all drug classes [20] Despite dissimilarities between European and American healthcare systems, comparable results were obtained in several analyses performed in the USA. It has been found that 15.4% of patients prescribed statins in managed care organization settings did not collect their prescriptions within 90 days of the order date [21] . In addition, 29.5% of women aged 55 years and older in integrated healthcare settings in California did not collect their bisphosphonate prescription within 60 days of the order date [22] . Furthermore, 34.0% of patients prescribed treatment for hypertension did not fulfil their prescription within 30 days [23] , and only 78% of all prescriptions issued in pediatric primary care were collected [24] .
Finally, among older adults consecutively discharged from a general internal medicine service at a large urban teaching hospital in Canada, 28% exhibited primary non-adherence at seven days after discharge, and 24% at 30 days after discharge. [25] Hence, the level of primary non-adherence observed in the first year of e-prescription use in Poland, did not deviate significantly from those observed in other countries.
Interestingly, 22.5% of all 195,930 e-prescriptions issued within the first year of communitybased e-prescription initiative in Massachusetts were not filled [26] .
Another interesting finding of our study is the effect of age on primary non-adherence rates. Despite expectations, the older age group tended to display a lower percentage of unfilled e-prescriptions, with the lowest values observed in those aged 75+: (16.1% in the general population, and 13.9% in a sample of selected drugs of key importance for chronic treatment, respectively). Similar observations have been made in other studies, across conditions and locations in Europe and the USA [17, 21, 26] . While it is possible that this greater compliance might be related to that greater motivation felt by seniors to take care of their health, adherence may also be affected by the presence of a carer, as some seniors are less independent in managing their own medication. However, further studies are needed to more precisely identify the determinants of lower rates of primary non-adherence in this age group.
Of utmost importance is our observation that primary non-adherence varied across therapeutic areas, drug classes and individual drugs. This has also been found to be the case in other studies [15, 26, 27, 28] .
Not surprisingly, out of the studied therapeutic areas, primary non-adherence was the lowest for antibiotics (14.3%). This most likely is associated with the symptomatic nature of the infections treated with these antibacterials. Other studies have provided similar findings [24] .
Among cardiovascular agents, the lowest primary non-adherence was found for ACE-I drugs (15.1%); this compares to 17.1% for beta blockers, 17.2% for angiotensin II receptor blockers, 18.0% for calcium channel blockers and 18.6% for diuretics. Interestingly, similar findings have been found in other countries: in one study of patients treated for newly diagnosed heart failure, the greatest level of compliance was observed for beta blockers, followed by ACE-Is [29] . In another study based on a large database of Catalonian eprescriptions, the lowest rate of primary non-adherence across all studied drug classes was observed for ACE-Is [20] . Perhaps one of the key drivers of this phenomenon is very low level of adverse effects in case of ACE-I, and the contrary in case of diuretics.
Several of our findings suggest that drug affordability may influence the rate of primary non-adherence. Firstly, primary non-adherence being generally low for diabetes area (14.9%), differed significantly across individual drugs. It is not surprising as some of these drugs are very affordable, being subject to only minimal patient copayment in Poland (approximately 3.00 PLN, i.e. 0.70 euro). In contrast, sitagliptin, incurring out-of-pocket patient copayment of approximately 140.00 PLN (app. 33.00 euro), due to lack of reimbursement, was associated with much higher rates of primary non-adherence (18.8%).
Similar scenario took place in case of antithrombotic agents, in which primary nonadherence ranged from 15.7% for Vitamin K antagonists (VKAs) to 20.2% for the more expensive direct thrombin inhibitors, belonging to the so-called novel oral anticoagulants (NOACs). Very similar results have been observed in Spain, with OR = 2.76 (95% CI = 2.41-3.15) being found for primary non-adherence for NOACs vs VKAs [14] . Despite having a more patient-friendly profile, with no need for continuous laboratory based monitoring or subsequent dose adjustment, NOACs are nevertheless much more costly than KVAs. In Poland, this corresponds with much higher patient copayment. Recent study in atrial fibrillation patients in Poland found high level of non-adherence for dabigatran [30] . Interestingly, with same drug we had observed the highest rate of primary non-adherence in our study.
Finally, the free availability of selected drugs for the oldest patients within the '75+
Program' also appears to have a beneficial effect on compliance. Indeed, higher drug costs have often been found to be drivers of primary non-adherence [13] . This was studied in more detail in an analysis performed in Catalonia, where the introduction of a fixed copayment was followed by a significant increase in primary non-adherence among the poorer population, low/middle-income pensioners and low-income non-pensioners (OR from 1.047 to 1.370), as well as a large, but statistically insignificant, increase among the high-income populations.
Primary non-adherence decreased again in the low-income population after suspension of the fixed copayment and the introduction of a coinsurance policy that granted this population free access to medication (OR=0.676). [31] Out of all drivers of primary non-adherence, pharmacy co-payments or out-of-pocket medication expenses represented the strongest association with poor initial adherence in terms of effect size or ORs in the systematic literature review. [28] The present study has certain limitations. Although the analysis of the e-prescription database allows for the identification of primary non-adherence in an objective, unbiased way, it does not provide any information on why a patient has not filled a prescription. Many such reasons are possible, from lack of trust in a diagnosis or a physician, the type of drug formulation, to high out-of-pocket costs: in Poland, patients are obliged to pay various copayments which vary according to the drug, indication, patient characteristics and so on [32] .
In addition, it was not possible to identify individual patients based on the range of data processed. Therefore, it was not possible to present initial non-adherence by the number of patients, nor to determine whether a particular e-prescription was the first for a particular patient or whether it occurred later in a series. For the same reasons, it was not possible to compare level of primary non-adherence to different drugs prescribed to a patient at the same time, and assess supposed prioritization. Finally, most of the analyzed e-prescriptions were issued within the course of the national e-prescription system pilot. The pilot run in selected locations only, which could lead to certain inclusion bias. Similarly, arrangements of this pilot could differ from usual care conditions a little. Nevertheless, we believe that all these limitations do not undermine the usefulness of our study, which both in terms of database size, and accuracy of data used are unique for Poland.
Conclusions
Our findings highlight the problem of primary non-adherence in Poland and identify several drivers of this phenomenon. Primary non-adherence varies across therapeutic areas, drug classes, and individual medicines. It is the least prevalent in the oldest patients. Drug affordability seems to be an important driver of this variation: prescriptions for drugs covered by the '75+ Program', which grants seniors free access to selected drugs for chronic conditions, are collected much more often than those outside the program.
The study proves that e-prescription system, an innovative eHealth solution currently implemented in Poland, provides unique opportunity to study primary non-adherence. Further studies combining e-prescription data with clinical data, both at the individual and national level, could shed even more light on this matter. The chances for this may come with nationwide implementation of the e-prescription system, which is expected from January 1 st , 2020. Nevertheless, our present findings offer practical recommendations for Polish public health and can play a significant role in designing national health policy.
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